Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer

Gabriella Ferrandina, Manuela Ludovisi, Giacomo Corrado, Vito Carone, Marco Petrillo, Giovanni Scambia

Research output: Contribution to journalArticle

Abstract

Objectives: The aim of the study was to investigate i) the association between the Ca125 based and the RECIST assessed response in recurrent ovarian cancer patients enrolled in a Phase III randomized trial (MITO-3) comparing salvage treatment with pegylated liposomal doxorubicin (PLD) versus gemcitabine (GEM); ii) the correlation between the early modifications of Ca125 levels during treatment and the RECIST assessed response; iii) the prognostic value of response based on Ca125 and the RECIST criteria. Methods: Assessment of response was performed by the RECIST and the GCIG criteria. The prognostic impact of the response by the RECIST criteria and the GCIG criteria was analyzed by the landmark method. Results: Overall, of 30 cases defined as responders on the basis of the GCIG criteria, 20 resulted as responders according to the RECIST criteria (NPV = 66.7%); conversely, 93.7% of the cases considered not responders based on the GCIG criteria were defined as unresponsive at RECIST evaluation. Early modifications of Ca125 levels were not completely predictive of the ultimate RECIST defined response. Overall survival (OS) was longer in RECIST defined responders versus non responders, although the statistical significance was not reached (p value = 0.092); conversely, median OS was significantly longer in GCIG defined responders than in non responding patients (p value = 0.0059). In multivariate analysis, the GCIG assessed response maintained its independent association with OS. Conclusions: GCIG criteria for tumor response could replace the conventional assessment of response in the decision making process relative to the discontinuation or prolongation of the salvage treatment in ovarian cancer.

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalGynecologic Oncology
Volume109
Issue number2
DOIs
Publication statusPublished - May 2008

Fingerprint

gemcitabine
Ovarian Neoplasms
Salvage Therapy
Survival
liposomal doxorubicin
Response Evaluation Criteria in Solid Tumors

Keywords

  • Ca125 response
  • Prognosis
  • Recurrent ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Prognostic role of Ca125 response criteria and RECIST criteria : Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. / Ferrandina, Gabriella; Ludovisi, Manuela; Corrado, Giacomo; Carone, Vito; Petrillo, Marco; Scambia, Giovanni.

In: Gynecologic Oncology, Vol. 109, No. 2, 05.2008, p. 187-193.

Research output: Contribution to journalArticle

@article{87d99865c467480ab568495367ec3995,
title = "Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer",
abstract = "Objectives: The aim of the study was to investigate i) the association between the Ca125 based and the RECIST assessed response in recurrent ovarian cancer patients enrolled in a Phase III randomized trial (MITO-3) comparing salvage treatment with pegylated liposomal doxorubicin (PLD) versus gemcitabine (GEM); ii) the correlation between the early modifications of Ca125 levels during treatment and the RECIST assessed response; iii) the prognostic value of response based on Ca125 and the RECIST criteria. Methods: Assessment of response was performed by the RECIST and the GCIG criteria. The prognostic impact of the response by the RECIST criteria and the GCIG criteria was analyzed by the landmark method. Results: Overall, of 30 cases defined as responders on the basis of the GCIG criteria, 20 resulted as responders according to the RECIST criteria (NPV = 66.7{\%}); conversely, 93.7{\%} of the cases considered not responders based on the GCIG criteria were defined as unresponsive at RECIST evaluation. Early modifications of Ca125 levels were not completely predictive of the ultimate RECIST defined response. Overall survival (OS) was longer in RECIST defined responders versus non responders, although the statistical significance was not reached (p value = 0.092); conversely, median OS was significantly longer in GCIG defined responders than in non responding patients (p value = 0.0059). In multivariate analysis, the GCIG assessed response maintained its independent association with OS. Conclusions: GCIG criteria for tumor response could replace the conventional assessment of response in the decision making process relative to the discontinuation or prolongation of the salvage treatment in ovarian cancer.",
keywords = "Ca125 response, Prognosis, Recurrent ovarian cancer",
author = "Gabriella Ferrandina and Manuela Ludovisi and Giacomo Corrado and Vito Carone and Marco Petrillo and Giovanni Scambia",
year = "2008",
month = "5",
doi = "10.1016/j.ygyno.2008.01.039",
language = "English",
volume = "109",
pages = "187--193",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Prognostic role of Ca125 response criteria and RECIST criteria

T2 - Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer

AU - Ferrandina, Gabriella

AU - Ludovisi, Manuela

AU - Corrado, Giacomo

AU - Carone, Vito

AU - Petrillo, Marco

AU - Scambia, Giovanni

PY - 2008/5

Y1 - 2008/5

N2 - Objectives: The aim of the study was to investigate i) the association between the Ca125 based and the RECIST assessed response in recurrent ovarian cancer patients enrolled in a Phase III randomized trial (MITO-3) comparing salvage treatment with pegylated liposomal doxorubicin (PLD) versus gemcitabine (GEM); ii) the correlation between the early modifications of Ca125 levels during treatment and the RECIST assessed response; iii) the prognostic value of response based on Ca125 and the RECIST criteria. Methods: Assessment of response was performed by the RECIST and the GCIG criteria. The prognostic impact of the response by the RECIST criteria and the GCIG criteria was analyzed by the landmark method. Results: Overall, of 30 cases defined as responders on the basis of the GCIG criteria, 20 resulted as responders according to the RECIST criteria (NPV = 66.7%); conversely, 93.7% of the cases considered not responders based on the GCIG criteria were defined as unresponsive at RECIST evaluation. Early modifications of Ca125 levels were not completely predictive of the ultimate RECIST defined response. Overall survival (OS) was longer in RECIST defined responders versus non responders, although the statistical significance was not reached (p value = 0.092); conversely, median OS was significantly longer in GCIG defined responders than in non responding patients (p value = 0.0059). In multivariate analysis, the GCIG assessed response maintained its independent association with OS. Conclusions: GCIG criteria for tumor response could replace the conventional assessment of response in the decision making process relative to the discontinuation or prolongation of the salvage treatment in ovarian cancer.

AB - Objectives: The aim of the study was to investigate i) the association between the Ca125 based and the RECIST assessed response in recurrent ovarian cancer patients enrolled in a Phase III randomized trial (MITO-3) comparing salvage treatment with pegylated liposomal doxorubicin (PLD) versus gemcitabine (GEM); ii) the correlation between the early modifications of Ca125 levels during treatment and the RECIST assessed response; iii) the prognostic value of response based on Ca125 and the RECIST criteria. Methods: Assessment of response was performed by the RECIST and the GCIG criteria. The prognostic impact of the response by the RECIST criteria and the GCIG criteria was analyzed by the landmark method. Results: Overall, of 30 cases defined as responders on the basis of the GCIG criteria, 20 resulted as responders according to the RECIST criteria (NPV = 66.7%); conversely, 93.7% of the cases considered not responders based on the GCIG criteria were defined as unresponsive at RECIST evaluation. Early modifications of Ca125 levels were not completely predictive of the ultimate RECIST defined response. Overall survival (OS) was longer in RECIST defined responders versus non responders, although the statistical significance was not reached (p value = 0.092); conversely, median OS was significantly longer in GCIG defined responders than in non responding patients (p value = 0.0059). In multivariate analysis, the GCIG assessed response maintained its independent association with OS. Conclusions: GCIG criteria for tumor response could replace the conventional assessment of response in the decision making process relative to the discontinuation or prolongation of the salvage treatment in ovarian cancer.

KW - Ca125 response

KW - Prognosis

KW - Recurrent ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=42749092093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749092093&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.01.039

DO - 10.1016/j.ygyno.2008.01.039

M3 - Article

C2 - 18343487

AN - SCOPUS:42749092093

VL - 109

SP - 187

EP - 193

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -